Evidence map›Paper›PMID 40001241›Full record

SynthesisBMC pharmacology & toxicology2025

Real world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: a meta-analysis of clinical studies.

Mohammad Amin Karimi, Hanieh Norooziseyedhosseini, Reza Khademi, Alireza Ghajary, Haniyeh Kargar, Seyyedeh Sana Abdollahi, Mohaddeseh Belbasi, Mahdyieh Naziri, Niloofar Deravi, Sajjad Hajihosseini and 1 more

Abstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in BMC pharmacology & toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Molecularly targeted therapy and immunotherapy in leukemias.Journal of hematology & oncology · 2026
    Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Mohammad Amin Karimi *School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Hanieh Norooziseyedhosseini *I.M. Sechenov First Moscow State Medical University, Moscow, Russia.
Reza Khademi *Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Alireza GhajarySchool of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.
Haniyeh KargarFaculty of Medicine, Islamic Azad University, Yazd Branch, Yazd, Iran.
Seyyedeh Sana AbdollahiStudent Research Committee, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran.
Mohaddeseh BelbasiStudents Research Committee, School of Pharmacy, Zanjan University of Medical Sciences, Zanjan, Iran.
Mahdyieh NaziriStudents Research Committee, School of Medicine, Iran University of Medical Sciences, Tehran, Iran. nazirimahdyieh@yahoo.com.
Niloofar DeraviSchool of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. niloofarderavi@sbmu.ac.ir.
Sajjad HajihosseiniStudent Research Committee, Tehran University of Medical Sciences, Tehran, Iran.
Saharnaz MofidiStudent Research Committee, Tehran University of Medical Sciences, Tehran, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundChronic lymphocytic leukemia (CLL) is a B-cell malignancy primarily diagnosed in older adults. For younger patients, treatment options often include regimens based on fludarabine, cyclophosphamide, and rituximab; however, at least 20% of patients exhibit resistance to these therapies. Ibrutinib, a covalent Bruton's tyrosine kinase (BTK) inhibitor, has demonstrated enhanced safety compared to conventional treatments. This meta-analysis examines the efficacy and safety of ibrutinib in managing relapsed/refractory CLL.

methodRelevant keywords were used to conduct a comprehensive search across online databases, including PubMed, Scopus, and Google Scholar. Data related to complete response (CR), overall response rate (ORR), and adverse events were extracted to evaluate the efficacy and safety of ibrutinib treatment. The results were presented in forest plots illustrating event rates and risk ratios with 95% confidence intervals (CI), while heterogeneity was assessed using I² statistics. Funnel plots were employed to examine potential publication bias visually.

resultTwenty-one studies were included in this meta-analysis. Ibrutinib as a single-agent treatment was associated with a 9% complete response (CR) rate (95% CI: 5-14%) and a 77% overall response rate (ORR) (95% CI: 70-83%). When combined with other agents, ibrutinib achieved a CR rate of 21% (95% CI: 9-41%) and an ORR of 84% (95% CI: 80-88%). Adverse events were not significantly correlated with treatment outcomes. Funnel plots indicated no significant publication bias.

conclusionSingle-agent ibrutinib has proven to be an effective therapy for patients with relapsed/refractory CLL. However, combining ibrutinib with other agents has demonstrated enhanced treatment efficacy. Further studies are needed to evaluate the safety profile of this therapeutic regimen thoroughly.

Indexed as

Antineoplastic AgentsLeukemia, Lymphocytic, Chronic, B-CellProtein Kinase InhibitorsPyrazolesPyrimidinesAdenineDrug Resistance, NeoplasmHumansPiperidinesRecurrenceTreatment OutcomeAdenineAntineoplastic AgentsibrutinibPiperidinesProtein Kinase InhibitorsPyrazolesPyrimidinesChronic lymphocyte leukemiaIbrutinibMeta-analysisRefractory CLLRelapsed CLL

Identifiers

PMID40001241
PMCPMC11853497

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.